Anti-Ro-52 antibodies have been associated with interstitial lung disease (ILD) in various autoimmune diseases. However, their role in ILD among patients with idiopathic inflammatory myopathies (IIMs) is relatively underexplored. This study aimed to investigate the association between anti-Ro-52 antibodies and the occurrence of ILD in individuals with IIMs. This retrospective observational study included 604 patients who underwent myositis autoantibody testing between July 2018 and January 2021 at our hospital and were diagnosed with either IIMs or IIM-mimics. Comparative analyses were conducted between IIMs and IIM-mimics, as well as within the IIM group between cases with and without ILD. Logistic regression or Firth’s logistic regression analyses were employed to assess the risk of ILD development in different IIM subgroups and myositis antibody categories. This study included 190 patients with IIM and 414 patients with IIM-mimics. Patients with IIM demonstrated higher incidence of ILD, concurrent autoimmune disease, and a greater likelihood of various myositis autoantibodies when compared to the IIM-mimics group. Within the IIM patient cohort, those with ILD exhibited a later age of onset of IIM, an increased mortality rate, and a more frequent presence of anti-aminoacyl-tRNA synthetase (ARS) antibodies compared to those without ILD. The presence of any myositis-specific antibody (MSA) was associated with a six-fold increased risk of ILD, while dual positivity for MSA and anti-Ro-52 antibodies conferred a twenty-fold risk. Anti-ARS antibodies carried a 14-fold increased risk of ILD, which escalated to 38-fold in cases of dual positivity for anti-ARS and anti-Ro-52 antibodies. Anti-Ro-52 antibodies alone increased the risk eight-fold. Among patients with IIM, the presence of ILD was linked to higher mortality. Certain autoantibodies, notably anti-ARS and anti-Ro-52 antibodies, were associated with an increased risk of ILD. The greatest risk of ILD was observed in cases of dual positivity for anti-ARS and anti-Ro-52 antibodies.

中文翻译：

---

特发性炎症性肌病患者抗Ro-52抗体与间质性肺疾病发生的关系


抗 Ro-52 抗体与多种自身免疫性疾病中的间质性肺病 (ILD) 相关。然而，它们在特发性炎症性肌病 (IIM) 患者间质性肺病 (ILD) 中的作用相对而言还没有得到充分研究。本研究旨在探讨抗 Ro-52 抗体与 IIM 患者 ILD 发生之间的关联。这项回顾性观察研究纳入了 604 名患者，他们于 2018 年 7 月至 2021 年 1 月期间在我们医院接受了肌炎自身抗体检测，并被诊断为 IIM 或 IIM 模拟患者。在 IIM 和 IIM 模拟物之间以及 IIM 组内有和没有 ILD 的病例之间进行了比较分析。采用逻辑回归或Firth逻辑回归分析来评估不同IIM亚组和肌炎抗体类别中ILD发展的风险。这项研究包括 190 名 IIM 患者和 414 名 IIM 模拟患者。与 IIM 模拟组相比，IIM 患者 ILD、并发自身免疫性疾病的发生率更高，并且出现各种肌炎自身抗体的可能性更大。在 IIM 患者队列中，与无 ILD 的患者相比，患有 ILD 的患者出现 IIM 的年龄较晚，死亡率较高，并且更频繁地出现抗氨酰基-tRNA 合成酶 (ARS) 抗体。任何肌炎特异性抗体 (MSA) 的存在都与 ILD 风险增加 6 倍相关，而 MSA 和抗 Ro-52 抗体双重阳性则导致 ILD 风险增加 20 倍。抗 ARS 抗体使 ILD 风险增加 14 倍，在抗 ARS 和抗 Ro-52 抗体双重阳性的情况下，ILD 风险增加至 38 倍。仅抗 Ro-52 抗体就会使风险增加八倍。 在 IIM 患者中，ILD 的存在与较高的死亡率有关。某些自身抗体，尤其是抗 ARS 和抗 Ro-52 抗体，与 ILD 风险增加相关。在抗 ARS 和抗 Ro-52 抗体双重阳性的病例中观察到 ILD 的最大风险。